Research Topics
| Edgardo RiveraSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Cost-effectiveness of influenza vaccination in working-age cancer patientsElenir B C Avritscher
Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 109:2357-64. 2007..In the current study, the authors analyzed the cost-effectiveness of influenza vaccination in working-age (ages 20-64 years) cancer patients...- Clinical model of lifetime cost of treating bladder cancer and associated complicationsElenir B C Avritscher
Section of Health Services Research, Department of Biostatistics and Applied Mathematics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Urology 68:549-53. 2006..To estimate the lifetime cost of bladder cancer and the contribution of complications to the total costs... - Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patientsElenir B C Avritscher
Division of Quantitative Sciences, Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
J Support Oncol 8:242-51. 2010..The cost-utility of palonosetron-based therapy exceeds the $100,000/QALY threshold. Future research incorporating the price structure of all antiemetics following ondansetron's recent patent expiration is needed... - Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosisElenir B C Avritscher
Section of Health Services Research, Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard Unit 196, Houston, TX 77030 4009, USA
Support Care Cancer 12:531-6. 2004.... - Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinomaEdgardo Rivera
Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 107:1348-54. 2006..A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer... 
Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancerEdgardo Rivera
Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 112:1455-61. 2008..The varying efficacy results and toxicity profiles noted in these earlier studies led to a comparison of the schedules to determine which was safer and more efficacious...- Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of diseaseEdgardo Rivera
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
Breast J 8:2-9. 2002..The benefit was greater on patients with node-negative primary tumors. In patients with stage IV-NED disease, doxorubicin-based chemotherapy should be considered standard treatment after adequate local control is achieved... - Outcomes and cost of deep venous thrombosis among patients with cancerLinda S Elting
Section of Health Services Research, Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
Arch Intern Med 164:1653-61. 2004..Furthermore, the cost of DVT is largely undescribed. We herein report the largest study of DVT in this population to date... - Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeksMarjorie C Green
The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
J Clin Oncol 23:5983-92. 2005.... - Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinomaEdgardo Rivera
Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 94:2321-6. 2002.... - Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancerEdgardo Rivera
Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 20:987-93. 2002..The primary objective of this study was to estimate the objective tumor response rate of orally administered eniluracil and 5-FU in the treatment of anthracycline- and taxane-resistant advanced breast cancer... - A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancerL Johnetta Blakely
Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 10:5425-31. 2004..The drug has linear pharmacokinetics, and in this heavily treated patient population, there was evidence of biological antitumor activity. A multi-institutional phase II study is planned... - Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxelBita Esmaeli
Section of Ophthalmology, Division of Pharmacy, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 24:3619-22. 2006..To determine the incidence and severity of epiphora and canalicular stenosis in patients receiving docetaxel weekly or every 3 weeks... - Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancerSilwan Chedid
Department of Breast Medical Oncology, M. D. Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Unit 424, Houston, TX, 77030-4095, USA
Cancer Chemother Pharmacol 57:540-4. 2006..Accurate risk stratification strategies can improve patients' selection and contribute to determine the appropriate benefit of therapies in MBC... - Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancerBita Esmaeli
Ophthalmology Section, Department of Plastic Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Ophthalmology 109:1188-91. 2002..Once complete or near complete stenosis of the canaliculi occurs, placement of a permanent Pyrex glass tube may become necessary to overcome the blockage of tear outflow... - Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancerBanu Arun
Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
Cancer Prev Res (Phila) 5:276-82. 2012..Anastrozole is currently being studied as a prevention agent in a large phase III trial and our results provide support for continued evaluation of IGFBP-1 as a surrogate endpoint biomarker in prospective breast chemoprevention studies... - Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancerEdgardo Rivera
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030 4009, USA
J Clin Oncol 21:3249-54. 2003..We conducted a phase II clinical trial to determine the clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer... - Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapyLajos Pusztai
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Cytokine 25:94-102. 2004..The objective of this study was to assess changes in plasma levels of interleukin (IL)-1beta, IL-6, IL-8, IL-10, IL-12, and TNF-alpha during chemotherapy and to correlate these changes with musculoskeletal symptoms... - Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancerLajos Pusztai
Box 424, Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
J Clin Oncol 21:3454-61. 2003..We studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patients with metastatic breast cancer (MBC)... - A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancerStacy Moulder
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 118:2378-84. 2012..Inhibition of mammalian target of rapamycin with everolimus may improve the efficacy of taxanes. Everolimus and docetaxel are both metabolized by CYP3A4, which could result in a pharmacokinetic (PK) interaction... - A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancerGabriel N Hortobagyi
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030 4009, USA
Cancer 116:1440-5. 2010..Orally administered UFT and leucovorin provided higher peak plasma concentrations of 5-FU and prolonged therapeutic 5-FU concentrations compared with continuous infusion of 5-FU... - Trends in recommendations of myelosuppressive chemotherapy for the treatment of breast cancer: evolution of the national comprehensive cancer network guidelines and the cooperative group studiesEdgardo Rivera
University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Clin Breast Cancer 7:33-41. 2006..Many oncologists are aware of this trend toward the more intensive treatment of patients with cancer and take proactive steps to minimize the risk of myelosuppression and its complications... - Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinomaLajos Pusztai
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer 104:682-91. 2005.... - Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancerEva Thomas
The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 25:3399-406. 2007..This international phase II trial assessed the activity of ixabepilone in patients with metastatic breast cancer (MBC) that was resistant to taxane therapy... - Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic optionsEdgardo Rivera
The Methodist Hospital Weill Cornell University, Houston, Texas, USA
Breast J 16:252-63. 2010..Further clinical evaluation of this agent in patients with drug-resistant breast cancer and in specific patient subsets is warranted... 
First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation studyEdgardo Rivera
University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
Breast Cancer Res 5:R114-20. 2003..This study was designed to validate an earlier published study based on a retrospective data analysis from a prospective randomized clinical trial...- Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifenEdgardo Rivera
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
Clin Cancer Res 10:1943-8. 2004.... - A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinomaFrancisco J Esteva
Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030, USA
Cancer 98:900-7. 2003..The objective of the current study was to determine the antitumor activity, safety, and pharmacokinetic (PK) profile of exatecan mesylate in patients with anthracycline-resistant and taxane-resistant, metastatic breast carcinoma... - Liposomal anthracyclines in metastatic breast cancer: clinical updateEdgardo Rivera
Department of Breast Medical Oncology, Division of Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Oncologist 8:3-9. 2003.... - Randomized pilot test of a lifestyle physical activity intervention for breast cancer survivorsKaren Basen-Engquist
The University of Texas M D Anderson Cancer Center, USA
Patient Educ Couns 64:225-34. 2006..The effect of the intervention on physical performance, quality of life, and physical activity are reported... - Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trialsBanu Arun
Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 13:4943-8. 2007..The optimum method to retrieve adequate samples and the most accepted method by study participants is not known... - Clinical development of ixabepilone and other epothilones in patients with advanced solid tumorsEdgardo Rivera
The Methodist Hospital Weill Cornell University, Houston, TX 77030, USA
Oncologist 13:1207-23. 2008..This review discusses the challenges of MDR and the data that support the use of epothilones in this setting, focusing on ixabepilone... - Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepiloneEdgardo Rivera
The Methodist Hospital Weill Cornell University, SM701, Houston, TX 77030, USA
Breast Cancer Res 12:S2. 2010..The present article reviews treatment options in taxane-resistant metastatic breast cancer and the role of ixabepilone in this setting... - Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanesEdgardo Rivera
Breast Medical Oncology Section, The Methodist Hospital Weill Cornell University, Houston, Texas 77030, USA
Am J Clin Oncol 33:176-85. 2010..Improved treatment strategies and further evaluation of newer agents may reduce the current burden of treatment-resistant or treatment-refractory MBC... - A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancerSharon H Giordano
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 8:3360-8. 2002..4%) who received a dose < or = 360 mg/m2 (P = 0.002). CONCLUSIONS: When the doxorubicin dose exceeds 360 mg/m2, the combination of bolus doxorubicin and paclitaxel presents unacceptable cardiac risk... - Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumorsLinda S Elting
The Section of Health Services Research, Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 97:1541-50. 2003..Another goal was to estimate the impact of depth and duration of thrombocytopenia on the cost of thrombocytopenia... - Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancerEdgardo Rivera
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
Cancer Chemother Pharmacol 49:299-302. 2002..We conducted a single-institution phase II clinical trial to determine the objective response rate, duration of response, time to progression, and overall survival in patients with anthracycline-resistant breast cancer treated with Doxil... - Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trialAman U Buzdar
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Clin Cancer Res 8:1073-9. 2002..In this prospective randomized trial, the role of paclitaxel was evaluated in an adjuvant setting to determine its impact on reducing the risk of recurrence in patients with operable breast cancer... - Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancerDaniel J Booser
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, Texas 77030 4095, USA
Cancer Chemother Pharmacol 50:6-8. 2002..L-AN at this dose and on this schedule had no detectable antitumor activity in patients with doxorubicin-resistant metastatic breast cancer... - Docetaxel secretion in tears: association with lacrimal drainage obstructionBita Esmaeli
Ophthalmology Section, Department of Plastic Surgery, Box 443, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Arch Ophthalmol 120:1180-2. 2002..To test the hypothesis that docetaxel may be secreted in tears after intravenous infusion... - Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patientsCarmen P Escalante
Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 437, Houston, TX 77030, USA
Support Care Cancer 12:657-62. 2004..The objectives were to determine the success of outpatient treatment of low-risk febrile neutropenia, to identify factors predicting outpatient failure, and to determine mortality related to the febrile episode... - Current status of liposomal anthracycline therapy in metastatic breast cancerEdgardo Rivera
University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0424, Houston, TX 77030, USA
Clin Breast Cancer 4:S76-83. 2003.... - Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasisKadri Altundag
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 110:2640-7. 2007..Several risk factors for CNS metastases have been reported. The objective of the current study was to describe clinicopathologic characteristics and prognostic factors in breast cancer patients with CNS metastases... - The role of statins in cancer therapyKatja Hindler
Division of Cardiovascular Anesthesiology, The Texas Heart Institute at St. Luke's Episcopal Hospital, 6720 Bertner Avenue, Houston, Texas 77030, USA
Oncologist 11:306-15. 2006..The feasibility and efficacy of statins for the prevention and treatment of cancer is reviewed... - Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk modelEdgardo Rivera
Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 0056, USA
Cancer 98:222-8. 2003..To the authors' knowledge, the current study is the first large prospective validation of a risk model in patients with early-stage breast carcinoma... - Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapyBita Esmaeli
Section of Ophthalmology, Department of Plastic Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 98:504-7. 2003..The current study was conducted to report the severity and management of canalicular and nasolacrimal duct stenosis as a side effect of docetaxel therapy and to report the outcomes of surgical intervention for this condition... - Efficacy and safety of liposomal anthracyclines in phase I/II clinical trialsDavid S Alberts
The Arizona Cancer Center, Tucson, AZ, USA
Semin Oncol 31:53-90. 2004.... - Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factorsEmer O Hanrahan
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Cancer 104:1158-71. 2005..The only significant independent prognostic factor was the number of involved axillary lymph nodes at initial diagnosis... - Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxelNuhad K Ibrahim
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
Clin Cancer Res 8:1038-44. 2002..Our results provide support for Phase II trials to determine the antitumor activity of this drug... - Expressive writing as a presurgical stress management intervention for breast cancer patientsJanet S de Moor
Division of Health Behavior and Health Promotion, The Ohio State University College of Public Health, Columbus, OH 43210, USA
J Soc Integr Oncol 6:59-66. 2008..EW was not broadly effective as a stress management intervention for women with breast cancer. These data do not support the use of EW as a presurgical mind-body complementary medicine program for this population... - Factors associated with participation in breast cancer treatment clinical trialsNancy E Avis
Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC 27157 1063, USA
J Clin Oncol 24:1860-7. 2006..It is well established that recruitment to clinical trials (CTs) is difficult and time consuming. This article reports on factors related to CT participation among women who were invited to participate in a CT for breast cancer...